The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 08, 2015

Filed:

Nov. 14, 2011
Applicants:

Patrick J. Sinko, Annandale, NJ (US);

Jieming Gao, New Brunswick, NJ (US);

Manjeet Deshmukh, Edison, NJ (US);

Xiaoping Zhang, Edison, NJ (US);

Matthew S. Palombo, Marmora, NJ (US);

Sherif Ibrahim, Old Bridge, NJ (US);

Inventors:

Patrick J. Sinko, Annandale, NJ (US);

Jieming Gao, New Brunswick, NJ (US);

Manjeet Deshmukh, Edison, NJ (US);

Xiaoping Zhang, Edison, NJ (US);

Matthew S. Palombo, Marmora, NJ (US);

Sherif Ibrahim, Old Bridge, NJ (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/385 (2006.01); A61K 9/51 (2006.01); A61K 31/337 (2006.01); A61K 31/4745 (2006.01); A61K 31/65 (2006.01); B82Y 5/00 (2011.01); A61K 45/06 (2006.01); A61K 31/519 (2006.01); A61K 31/555 (2006.01); A61K 31/675 (2006.01); A61K 31/704 (2006.01); C08G 65/329 (2006.01);
U.S. Cl.
CPC ...
A61K 9/5146 (2013.01); A61K 31/337 (2013.01); A61K 31/385 (2013.01); A61K 31/4745 (2013.01); A61K 31/519 (2013.01); A61K 31/555 (2013.01); A61K 31/65 (2013.01); A61K 31/675 (2013.01); A61K 31/704 (2013.01); A61K 45/06 (2013.01); B82Y 5/00 (2013.01); C08G 65/329 (2013.01); C08L 2203/02 (2013.01);
Abstract

Non-Small Cell Lung Carcinomas (NSCLCs) are treated with Gel Micro-Particles (GMPs) that passively accumulate in the lungs and contain Nano-Particles (NPs) combining one or more therapeutic agents that are cytotoxic to the NSCLC with one or more NSCLC active targeting ligands, as well as one or more other optional agents that increase cellular uptake, enhance the pro-apoptotic effect of the chemotherapeutic agent(s), and the like. NPs targeting other cancer cells are also disclosed, as well as NP-containing GMPs that reduce the occurrence of tumor metastasis.


Find Patent Forward Citations

Loading…